ABSTRACT
Vitiligo is a chronic autoimmune skin disorder whose diagnosis is often psychologically upsetting. The efficacy of the available therapies, including topical corticosteroids and topical calcineurin inhibitors, has historically been limited and the management of vitiligo is still challenging. As vitiligo is a chronic disease limited to the skin, topical rather than systemic therapies may be preferable (especially among patients with localised lesions) to avoid the long-term side-effects of the latter. A topical formulation of ruxolitinib, a selective JAK1/2 inhibitor, has recently been approved in the United States for the treatment of non-segmental vitiligo in patients aged >12 years based on data from the phase III TRuE-V1 and TRuE-V2 clinical trials. The aim of this review is to describe the current evidence concerning the efficacy and safety of topical ruxolitinib in the treatment of vitiligo, and discuss issues regarding its use in younger children and pregnant or breastfeeding women, as well as the duration and durability of treatment. The promising results obtained so far suggest that 1.5% ruxolitinib cream is an effective means of treating vitiligo.
Subject(s)
Janus Kinase Inhibitors , Vitiligo , Child , Humans , Female , Vitiligo/drug therapy , Nitriles , Pyrimidines/therapeutic use , Calcineurin Inhibitors/therapeutic use , Janus Kinase Inhibitors/therapeutic use , Treatment OutcomeABSTRACT
BACKGROUND: Rosacea is an inflammatory condition of the face characterized in its early stages by flushing, erythema and telangiectasias. OBJECTIVES: We evaluate the efficacy of long-pulsed Nd:YAG laser on erythematousteleangiectasic rosacea (ETR). METHODS: In a retrospective case study of 21 patients (14F, 7M) with an average age of 29â¯years (range 19-41), were treated with two sessions at a distance of one month, with phototype up to III (5 phototype 1, 14 phototype II, 2 phototype III) with a fluence of 20â¯J/cm2. RESULTS: We observed a reduction of the erythematous component between 50% and 80% after two sessions, with an average pain score attributed to the treatment, measured by visual analogue scale (VAS), of 3. CONCLUSION: In this case series in which Nd:YAG laser had been used with a "'in motion" technique, we observed a reduction of the side effects and pain.
Subject(s)
Lasers, Solid-State , Rosacea , Telangiectasis , Humans , Young Adult , Adult , Lasers, Solid-State/therapeutic use , Retrospective Studies , Rosacea/radiotherapy , Erythema/etiology , Telangiectasis/radiotherapy , Telangiectasis/etiology , Pain/etiology , Treatment OutcomeABSTRACT
Atopic dermatitis (AD) is a chronic, inflammatory skin disorder that most frequently occurs in children, but it can also affect adults. Even though most AD cases can be managed with topical treatments, moderate-to-severe forms require systemic therapies. Dupilumab is the first human monoclonal antibody approved for the treatment of AD. Its action is through IL-4 receptor alpha subunit inhibition, thus blocking IL-4 and IL-13 signaling pathways. It has been shown to be an effective, well-tolerated therapy for AD, as well as for asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and eosinophilic esophagitis (EoE). However, an increasing incidence of dupilumab-induced ocular surface disease (DIOSD) has been reported in patients treated with dupilumab, as compared to placebo. The aim of this study was to summarize scientific data regarding DIOSD in AD patients treated with dupilumab. A search of PubMed and clinicaltrials.gov databases was performed. There was no limit to study design. All AD cases were moderate-to-severe. DIOSD was either dermatologist-, allergist-, or ophthalmologist-assessed. Evidence shows that DIOSD occurs most frequently in patients with atopic dermatitis and not in other skin conditions, neither in patients with asthma, CRSwNP, nor EoE who are on dupilumab treatment. Further studies are warranted in order to establish a causal relationship between dupilumab and ocular surface disease. Nevertheless, ophthalmological evaluations prior to dupilumab initiation can benefit AD patients with previous ocular pathology or current ocular symptomatology. Also, patch testing for ocular allergic contact dermatitis might be advantageous in patients with a history of allergic conjunctivitis. Furthermore, TARC, IgE, and circulating eosinophils levels might be important biomarkers for a baseline assessment of future candidates to dupilumab treatment. However, TARC measurements should be resumed for research purposes only.
Subject(s)
Antibodies, Monoclonal, Humanized , Dermatitis, Atopic , Antibodies, Monoclonal, Humanized/adverse effects , Dermatitis, Atopic/drug therapy , Humans , Interleukin-4 Receptor alpha Subunit , Severity of Illness Index , Treatment OutcomeSubject(s)
COVID-19 Vaccines , COVID-19 , Administration, Cutaneous , Humans , Italy , RNA , SARS-CoV-2ABSTRACT
BACKGROUND: Among the various types of basal cell carcinoma, the sclerodermiform variant has a high risk of recurrence and local invasiveness. A systematic description of the dermatoscopic features associated with specific body localization is lacking. OBJECTIVES: To describe the clinical and dermoscopic features of sclerodermiform basal cell carcinoma (BCC) according to localization in the body confronting with superficial and nodular types. METHODS: Clinical and dermoscopic images of sclerodermiform, nodular and superficial BCCs were retrospectively evaluated to study the location in the various body districts, maximum diameter, clinical appearance of the lesion, features of edges and presence or absence of specific dermatoscopic criteria of BCCs. RESULTS: We examined 291 histopathologically proven BCCs showing that in nodular BCCs, classical arborizing vessels were more frequently found in the body macro-area (trunk and limbs; n = 46, 97.9%) than in the head/neck area (n = 43, 82.7%); within sclerodermiform BCCs, short arborizing vessels were found more frequently in the head/neck district (n = 35, 49.3%) than in the body (n = 6, 23.1%; P-value 0.02); within nodular BCCs, multiple blue-grey dots and globules were more frequently found on the trunk (n = 23, 48.9%) than in the head/neck district (n = 12, 23.1%; P-value 0.01). In sclerodermiform BCCs, ulceration was found more frequently in the head/neck district (n = 38, 53.5%) than in the body (n = 4, 15.4%; P-value > 0.01), and in superficial BCCs, ulceration was found more frequently in the head/neck district (n = 5, 38.5%) than in the body (n = 8, 9.8%; P-value 0.02). CONCLUSION: Our study shows that superficial BCC are found frequently in the head/neck district dermoscopically characterized by ulceration and arborizing vessels; nodular BCCs are more frequently found in the body than in the head/neck district, and the dermoscopic pattern is characterized by the combination of three features: (i) classical arborizing vessels, (ii) multiple blue-grey dots and (iii) globules. Instead, sclerodermiform BCC is preferentially located in areas at high-moderate risk of recurrence; if pink-white areas and/or fine arborizing vessels are seen, clinicians should consider this diagnosis. Furthermore, location-specific dermatoscopic criteria have been described.
Subject(s)
Carcinoma, Basal Cell , Skin Neoplasms , Carcinoma, Basal Cell/diagnostic imaging , Demography , Dermoscopy , Humans , Neoplasm Recurrence, Local , Retrospective Studies , Skin Neoplasms/diagnostic imagingSubject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Psoriasis/chemically induced , Spondylitis, Ankylosing/drug therapy , Antibodies, Monoclonal, Humanized/administration & dosage , Dermoscopy , Female , Humans , Injections, Subcutaneous , Middle Aged , Psoriasis/diagnosis , Skin/pathologyABSTRACT
BACKGROUND: Epidemiologic data suggest an increased risk of melanoma (MM) and non-melanoma skin cancer (NMSC) in persons with intense recreational sun-exposure such as marathon runners or surfers. Up to data little is known about the sun-exposure habits, sun-protection behaviours and risk factors for MM and NMSC among sailors. OBJECTIVE: The objective of this prospective, cross-sectional study was to investigate the sun-exposure and sun-protective habits and risk factors for skin cancer among sailors attending the 50° edition of Barcolana, the largest sailing race in of the world, which took place in October 2018 in Trieste, Italy as an integrative component of a public sun-prevention campaign. METHODS: The study consisted of 2 parts: (i) a self-administered questionnaire focusing on sun-exposure and protective habits and (ii) a free skin examination carried out by volunteer dermatologists. Participation was optional and anonymous, and open to visitors and sailors attending the event. RESULTS: Overall, 431 (52.4%) sailors and 391 (47.6%) visitors responded to the questionnaire, while a total of 437 individuals including 189 (43.3%) sailors and 248 (56.6%) visitors participated in the skin examination group. The majority of sailors reported a past history of severe sunburns (20.2%), applied sunscreen never (14.4%) to sometimes (45.7%) or only once daily (59%) on the face (55%) and shoulders (26%). Moreover, 14% of sailors had a personal history of non-melanoma skin cancer (NMSC). During the dermatological examination, suspicious lesions for skin cancer (including MM and NMSC) were identified in 37% of the sailors. CONCLUSION: Our findings support the need to develop and promote primary and secondary prevention strategies to improve the sun-exposure and sun-protective habits among sailors.
Subject(s)
Environmental Exposure , Skin Neoplasms/prevention & control , Sunlight , Sunscreening Agents/administration & dosage , Female , Humans , Italy , Male , Prospective Studies , Surveys and QuestionnairesABSTRACT
Keratinocyte cancers - basal and cutaneous squamous cell carcinoma (BCC, cSCC) - are the most common forms of non-melanoma skin cancer (NMSC) and there has been a significant increase in their incidence globally in recent decades. Although the majority of BCC and cSCC are cured with conventional surgery or radiotherapy, certain tumour or patient-determined factors may result in these modalities being inadequate or inappropriate, for example, locally advanced or metastatic disease, high tumour multiplicity, patient comorbidities and patient preferences. In these clinical circumstances, systemic treatment may be indicated, and over the past 10 years a number of new systemic agents have been approved. Nonetheless, effective systemic therapy for keratinocyte cancers remains an area of significant unmet clinical need. Improved understanding of the molecular and immune pathogenesis underlying tumour growth and development is critical for driving future advances and is a research priority. The aim of this review is to provide clinicians with an overview of systemic treatments for BCC and cSCC and will focus on current evidence for conventional chemotherapy, targeted therapies, immunotherapy, adjuvant and neoadjuvant therapy, chemoprevention and future prospects for novel systemic treatment approaches.
Subject(s)
Carcinoma, Squamous Cell/drug therapy , Skin Neoplasms/drug therapy , Carcinoma, Squamous Cell/pathology , Humans , Skin Neoplasms/pathologySubject(s)
Carcinoma, Squamous Cell , Keratoacanthoma , Papillomaviridae , Papillomavirus Infections , Skin Neoplasms , HumansSubject(s)
Alphapapillomavirus/isolation & purification , Carcinoma, Squamous Cell/virology , Keratoacanthoma/virology , Papillomavirus Infections/pathology , Skin Neoplasms/virology , Aged , Aged, 80 and over , Alphapapillomavirus/pathogenicity , Carcinogenesis/pathology , Carcinoma, Squamous Cell/pathology , Female , Humans , Keratoacanthoma/pathology , Male , Middle Aged , Papillomavirus Infections/virology , Pilot Projects , Retrospective Studies , Skin/pathology , Skin/virology , Skin Neoplasms/pathologyABSTRACT
Pigmented Bowen disease (pBD) is an uncommon variant of squamous cell carcinoma in situ. Sometimes it can show clinical and dermoscopic features that are seen in other pigmented lesions of the skin and mucosa, making the diagnosis difficult. We report six cases of pBD occurring on the anogenital area, and discuss the importance of dermoscopy for improving the diagnostic accuracy in pBD.
Subject(s)
Bowen's Disease/diagnosis , Dermoscopy , Skin Neoplasms/diagnosis , Urogenital Neoplasms/diagnosis , Aged , Bowen's Disease/pathology , Female , Humans , Male , Middle Aged , Skin Neoplasms/pathology , Urogenital Neoplasms/pathologyABSTRACT
OBJECTIVE: To determine the association, if any, between the human spermatic membrane integrity test and normal or altered membrane ABH glycosphingolipids expression. METHODS: Semen samples from 50 patients who consulted at the infertility services of the Provincial del Centenario and Eva Peron de Granadero Belgorria teaching hospitals in Rosario (Argentina) were collected and analyzed in accordance with WHO guidelines. The percentage of dead sperm was analyzed by the eosin test while the percentage of swollen sperm was analyzed by the hypoosmotic test. They were classified according to their ABH expression, either diminished or absent (group 1) or normal (group 2), by applying the hemagglutination inhibition and specific antibody consumption technique. For the statistical analysis the two groups were compared with both spermatic viability tests using the non parametric Mann-Whitney technique for independent samples, since the assumptions for the application of the parametric test (test t) were not fulfilled. RESULTS: A significant difference was found in the percentage of dead sperm (eosin test) of both groups (p < 0.001). However, there was no significant difference in the percentage of swollen sperm (hypoosmotic test) of the two groups. CONCLUSIONS: Our results and the data published in the literature indicate a relationship between a reduced ABH expression and spermatozoid membrane integrity, especially at the level of the head, which leads us to consider that ABH glycosphingolipids are mainly located in this segment of the human spermatozoon involved in the spermatozoon-ovum interactions.
Subject(s)
ABO Blood-Group System/biosynthesis , Glycosphingolipids/biosynthesis , Spermatozoa/metabolism , Humans , Male , Spermatozoa/pathologyABSTRACT
OBJECTIVE: To investigate the occurrence of antisperm antibodies (ASAs) and their correlation to semen parameters in varicocele patients. METHODS: Semen samples from 137 patients with unilateral palpable clinical varicocele aged 15-35 years who consulted at the Infertility and Urology services of the Provincial del Centenario and Eva Peron teaching hospitals in Rosario (Argentina) were collected and analyzed according to the WHO standardized protocols and ASAs were tested with TAC II. Statistical analyses were performed using log linear models. RESULTS: Motility was impaired in 67.2% (p < 0.001) and morphology in 97.1%. Sperm concentration decreased in 19.7%, although it was not statistically different from that of the normal population. Of the infertile population with varicocele, 46.7% had positive ASAs with TAC II. CONCLUSIONS: We found a statistically significant correlation only between motility and sperm count (p < 0.01). Our study indicates that the severe dysspermia observed may be caused by autoimmune processes that trigger cellular and humoral mechanisms.